|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Wake Forest University School of Medicine
2 First Department of Internal Medicine, Miyazaki
* To whom correspondence should be addressed. E-mail: jjessup{at}wfubmc.edu.
Low expression of angiotensinogen in the heart has been construed as indicating a circulating uptake mechanism to explain the local effects of angiotensin II on tissues. The recent identification of angiotensin-(1-12) in an array of rat organs suggests this propeptide may be an alternate substrate for local angiotensin production. To test this hypothesis, tissues from 11 week old SHR and WKY rats [n = 14] were stained with purified antibodies directed to the C-terminus of angiotensin-(1-12). Robust angiotensin-(1-12) staining was predominantly found in ventricular myocytes with less staining found in the medial layer of intra-coronary arteries and vascular endothelium. In addition, angiotensin-(1-12) immunoreactivity was present in the proximal, distal, and collecting renal tubules within the deep cortical and outer medullary zones in both strains. Pre-adsorption of the antibody with angiotensin-(1-12) abolished staining in both tissues. Corresponding tissue measurements by radioimmunoassay showed 47% higher levels of angiotensin-(1-12) in the heart of SHR compared to WKY (P < 0.05). In contrast, renal angiotensin-(1-12) levels were 16.5% lower in SHR compared to the WKY (P < 0.05). This study shows for first time the localization of angiotensin-(1-12) in both cardiac myocytes and renal tubular components of WKY and SHR rats. In addition, we show that increased cardiac angiotensin-(1-12) concentrations in SHR is associated with a small, but statistically significant reduction in renal angiotensin-(1-12) levels.
This article has been cited by other articles:
![]() |
K. Isa, M. A. Garcia-Espinosa, A. C. Arnold, N. T. Pirro, E. N. Tommasi, D. Ganten, M. C. Chappell, C. M. Ferrario, and D. I. Diz Chronic immunoneutralization of brain angiotensin-(1-12) lowers blood pressure in transgenic (mRen2)27 hypertensive rats Am J Physiol Regulatory Integrative Comp Physiol, July 1, 2009; 297(1): R111 - R115. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Whaley-Connell, J. Habibi, Y. Wei, A. Gutweiler, J. Jellison, C. E. Wiedmeyer, C. M. Ferrario, and J. R. Sowers Mineralocorticoid receptor antagonism attenuates glomerular filtration barrier remodeling in the transgenic Ren2 rat Am J Physiol Renal Physiol, May 1, 2009; 296(5): F1013 - F1022. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. M. Cummins A new addition to the renin-angiotensin peptide family: proAngiotensin-12 (PA12) Cardiovasc Res, April 1, 2009; 82(1): 7 - 8. [Full Text] [PDF] |
||||
![]() |
C. M. Ferrario, J. Varagic, J. Habibi, S. Nagata, J. Kato, M. C. Chappell, A. J. Trask, K. Kitamura, A. Whaley-Connell, and J. R. Sowers Differential regulation of angiotensin-(1-12) in plasma and cardiac tissue in response to bilateral nephrectomy Am J Physiol Heart Circ Physiol, April 1, 2009; 296(4): H1184 - H1192. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. C.G. Prosser, M. E. Forster, A. M. Richards, and C. J. Pemberton Cardiac chymase converts rat proAngiotensin-12 (PA12) to angiotensin II: effects of PA12 upon cardiac haemodynamics Cardiovasc Res, April 1, 2009; 82(1): 40 - 50. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. I. Diz Future Directions in Cardiovascular Pharmacology: Examples from the Renin-Angiotensin System Mol. Interv., October 1, 2008; 8(5): 222 - 225. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| Visit Other APS Journals Online |